Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Debt / NOTE 1.750% 2/1
-
Number of holders
-
29
-
Total 13F principal, excl. options
-
245,718,242
-
Principal change
-
-8,928,179
-
Total reported value, excl. options
-
$198,931,644
-
Value change
-
-$16,150,064
-
Number of buys
-
14
-
Number of sells
-
17
-
Price
-
$0.8047
Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q3 2023
As of 30 Sep 2023 REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 had 37 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $245,718,242 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included FRANKLIN RESOURCES INC, D. E. Shaw & Co., Inc., Graham Capital Management, L.P., AVIVA PLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, UBS OCONNOR LLC, Linden Advisors LP, CAPSTONE INVESTMENT ADVISORS, LLC, SSI INVESTMENT MANAGEMENT LLC, and CSS LLC/IL.
This table shows 37 bond principal holders of the security as of 30 Sep 2023.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.